ProMIS Neurosciences to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

ProMIS Neurosciences

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. — January 6, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10–13, 2022.

 

A webcast of the pre-recorded presentation will be made available at 7:00 AM ET on Monday, January 10th and will be available under "News and Events" in the Investors section of the company's website at https://www.promisneurosciences.com/investors/news-events.

 

ProMIS Executive Chairman and CEO, Eugene Williams, will provide an update on the company with an overview of its unique technology platform that has enabled ProMIS to develop a broad portfolio of antibody candidates selectively targeting toxic misfolded proteins in multiple neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD), among others. In addition, the presentation will focus on PMN310, ProMIS’ oligomer-selective lead antibody for AD, currently in late preclinical development/IND enabling studies.

 

About ProMIS Neurosciences

 

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF

 

Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn

 

For Investor Relations please contact:

Alpine Equity Advisors

Nicholas Rigopulos, President

nick@alpineequityadv.com

Tel. 617 901-0785

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

###